Brokers Issue Forecasts for Intelligent Bio Solutions Inc.’s Q4 2023 Earnings (NASDAQ:INBS)

Posted by on Jun 7th, 2023

Intelligent Bio Solutions Inc. (NASDAQ:INBS – Get Rating) – Equities researchers at Zacks Small Cap issued their Q4 2023 earnings per share (EPS) estimates for Intelligent Bio Solutions in a note issued to investors on Monday, June 5th. Zacks Small Cap analyst J. Vandermosten anticipates that the company will earn ($1.66) per share for the quarter. The consensus estimate for Intelligent Bio Solutions’ current full-year earnings is ($1.74) per share. Zacks Small Cap also issued estimates for Intelligent Bio Solutions’ FY2025 earnings at ($2.73) EPS.

Intelligent Bio Solutions Stock Performance

INBS stock opened at $3.01 on Tuesday. Intelligent Bio Solutions has a twelve month low of $2.09 and a twelve month high of $32.00. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.25. The stock’s 50 day moving average is $2.85 and its 200-day moving average is $5.77.

Institutional Trading of Intelligent Bio Solutions

A hedge fund recently bought a new stake in Intelligent Bio Solutions stock. Sabby Management LLC acquired a new stake in shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS – Get Rating) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 126,650 shares of the company’s stock, valued at approximately $367,000. Intelligent Bio Solutions accounts for approximately 0.3% of Sabby Management LLC’s holdings, making the stock its 26th largest position. Sabby Management LLC owned approximately 8.52% of Intelligent Bio Solutions as of its most recent SEC filing. 2.28% of the stock is currently owned by hedge funds and other institutional investors.

Intelligent Bio Solutions Company Profile

(Get Rating)

Intelligent Bio Solutions Inc, a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.

Featured Stories

Receive News & Ratings for Intelligent Bio Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Bio Solutions and related companies with MarketBeat.com's FREE daily email newsletter.